CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

CAT

888.24

-3.43%↓

281.82

-3.3%↓

GEV.US

1,047.58

-3.79%↓

RTX

171.14

-2.6%↓

220.49

-3.9%↓

Home・Stock List・Ocugen Inc

Ocugen Inc

Closed

1.39 -4.14

Buy Sell

Overview

Share price change

24h

Current

Min

1.38

Max

1.3900000000000001

Key metrics
By Trading Economics
Income	-1.5M -19M
Sales	1.7M 1.5M
EPS	-0.06
Profit margin	-1,250.946
Employees	116
EBITDA	-987K -17M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+732.37% upside

Dividends
By Dow Jones
Next Earnings	31 Jul 2026

Market Stats
By TradingEconomics
Market Cap	-125M 501M
Previous open	5.53
Previous close	1.39

Technical Score

By Trading Central

Confidence

Strong Bearish Evidence

0.6818 / 0.74 Support & Resistance

Ocugen Inc Chart

Past performance is not a reliable indicator of future results.

Related News

15 May 2026, 22:47 UTC

Hot Stocks

Stocks to Watch: Macy's, Delta, UnitedHealth, NextNRG

15 May 2026, 22:16 UTC

Acquisitions, Mergers, Takeovers

Canadian Tribunal Gives Keyera, Plains Until Late June to Rebut Bid to Undo Merger

15 May 2026, 22:00 UTC

Major Market Movers

Delta Air Shares Rise as Berkshire Hathaway Discloses Stake

15 May 2026, 18:09 UTC

Major Market Movers

Palo Alto Shares Head for Record-High Close, Analysts See Benefits to Identity Security Pivot

15 May 2026, 16:02 UTC

Earnings

Major Market Movers

Forward Industries Shares Fall on New Debt as Solana Value Drops

15 May 2026, 14:55 UTC

Major Market Movers

Aardvark Therapeutics Shares Plunge After FDA Hold on ARD-101 New Drug Application

15 May 2026, 14:43 UTC

Major Market Movers

Chip Stocks Slide After U.S.-China Summit Ends Without Major Tech Deals -- Update

15 May 2026, 22:17 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:59 UTC

Acquisitions, Mergers, Takeovers

Stanley Druckenmiller Just Exited Alphabet. TCI Fund Management Is Buying. -- Barrons.com

15 May 2026, 21:50 UTC

Acquisitions, Mergers, Takeovers

Berkshire Boosted Stake in Alphabet in First Quarter, Bought Delta Air, Sold Visa, Mastercard -- Barrons.com

15 May 2026, 21:30 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 4th Update

15 May 2026, 21:16 UTC

Market Talk

Canada Oil Producers Expect Govt Cash Before Building Pathways Project -- Market Talk

15 May 2026, 20:50 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 20:19 UTC

Hot Stocks

Stocks to Watch Recap: Intel, Nvidia, Amgen, LVMH -- WSJ

15 May 2026, 19:41 UTC

Acquisitions, Mergers, Takeovers

SanDisk Stock Is Up 494% This Year. Insiders Are Cashing In on the AI-Fueled Surge. -- Barrons.com

15 May 2026, 19:35 UTC

Market Talk

Oil Futures Settle Higher on Inventory Worries -- Market Talk

15 May 2026, 19:33 UTC

Market Talk

U.S. Natural Gas Futures Rise as Weather Heats Up -- Market Talk

15 May 2026, 18:35 UTC

Earnings

Xanadu Quantum Revenue Increases Fourfold. Why the Stock Is Falling. -- Barrons.com

15 May 2026, 17:28 UTC

Market Talk

U.S. Oil Rig Count Rises by 5 to 415 -- Market Talk

15 May 2026, 16:50 UTC

Acquisitions, Mergers, Takeovers

Microsoft Stock Moves Higher After Ackman Announces New Stake -- WSJ

15 May 2026, 16:24 UTC

Acquisitions, Mergers, Takeovers

Bill Ackman's Pershing Square Bets on Microsoft's AI Ambitions With New Stake -- 3rd Update

15 May 2026, 16:20 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Auto & Transport Roundup: Market Talk

15 May 2026, 16:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

15 May 2026, 15:55 UTC

Market Talk

Canada's 1Q Rebound Not a Turning Point -- Market Talk

15 May 2026, 15:20 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

15 May 2026, 15:20 UTC

Market Talk

Silver Plunges on Inflation Worries -- Market Talk

15 May 2026, 15:20 UTC

Earnings

A Micron and Sandisk Peer Is Coming to U.S. Markets. What to Know About Japan's Kioxia. -- Barrons.com

15 May 2026, 14:33 UTC

Market Talk

Dollar Could Drift Higher as it Retains High-Yielding Status -- Market Talk

Peer Comparison

Price change

Ocugen Inc Forecast

Price Target

By TipRanks

732.37% upside

12 Months Forecast

Average 11.57 USD 732.37%

High 22 USD

Low 7 USD

Based on 7 Wall Street analysts offering 12 month price targets forOcugen Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

7 ratings

Buy

Hold

Sell

Based on 7 analysts giving stock ratings to Ocugen Inc - Dist in the past 3 months.

Technical Score

By Trading Central

0.6818 / 0.74Support & Resistance

Recent bearish events outweigh bullish events.

Recent bullish events outweigh bearish events.

There are no events.

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ocugen Inc

Ocugen, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing novel gene and cell therapies and vaccines that improve patients' health. The company's pipeline product includes OCU400, a novel gene therapy product candidate restoring retinal integrity and function across a range of genetically diverse inherited retinal diseases, currently under Phase 3 trials for the treatment of retinitis pigmentosa and Phase 1/2 trials for the treatment of leber congenital amaurosis; OCU410, a gene therapy under phase 1/2 for the treatment of dry age-related macular degeneration (AMD); and OCU410ST, a gene therapy under phase 1/2 for the treatment of Stargardt disease. It is also involved in the development of OCU200, a novel fusion protein that is in preclinical development stage for the treatment of diabetic macular edema, diabetic retinopathy, and wet age-related macular degeneration; and NeoCart, an autologous chondrocyte-derived neocartilage, currently under Phase 3 studies indicated for the repair of knee cartilage injuries in adult. In addition, the company is developing OCU500, a COVID-19 vaccine; OCU510, a seasonal quadrivalent flu vaccine; and OCU520, a combination quadrivalent seasonal flu and COVID-19 vaccine. It has collaboration agreements with National Institute of Allergy and Infectious Diseases for early clinical studies for the OCU500 program; and a strategic partnership with CanSino Biologics Inc. for manufacturing its modifier gene therapy pipeline product candidates. The company was founded in 2013 and is headquartered in Malvern, Pennsylvania.